Vectibix — Total revenues
Products & Services · Total revenuesAmgen Vectibix — Total revenues remained flat by 0.0% to $293.75M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 12.4%, from $261.25M to $293.75M. Over 2 years (FY 2023 to FY 2025), Vectibix — Total revenues shows an upward trend with a 9.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong market demand, successful clinical adoption, or effective pricing strategies for the oncology product, while a decrease may signal increased competition, patent expiration, or shifts in clinical treatment guidelines.
Detailed definition
This metric represents the total gross sales generated from the global commercialization of a specific oncology therapeu...
Peer comparison
Comparable to oncology product revenue lines at other large-cap biotechnology or pharmaceutical firms, often benchmarked against market share in specific therapeutic areas.
amgn_segment_vectibix_total_revenuesHistorical Data
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $984.00M | $1.05B | $1.18B |
| YoY Change | — | +6.2% | +12.4% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Amgen's vectibix — total revenues?
- Amgen (AMGN) reported vectibix — total revenues of $293.75M in Q4 2025.
- How has Amgen's vectibix — total revenues changed year-over-year?
- Amgen's vectibix — total revenues increased by 12.4% year-over-year, from $261.25M to $293.75M.
- What is the long-term trend for Amgen's vectibix — total revenues?
- Over 2 years (2023 to 2025), Amgen's vectibix — total revenues has grown at a 9.3% compound annual growth rate (CAGR), from $984.00M to $1.18B.
- What does vectibix — total revenues mean?
- The total revenue generated from the sales of the Vectibix oncology therapeutic product.